LG Chem releases DPP-4+SGLT-2 combo Zemidapa Tab

“Will release the drug on the 8th...may be prescribed with reimb from the 1st next month”

“Phase III trial conducted on 800 patients... confirmed a decrease in blood glucose level in the trial”

On the 4th, LG Chem announced it will be releasing its new antidiabetic combination drug ‘Zemidapa Tab’ on the 8th.

 

Zemidapa is a fixed-dose combination of the DPP-4 inhibitor class market leader Zemiglo (gemigliptin) and SGLT-2 inhibitor class market leader dapagliflozin (Product name: Forxiga).

 

Zemidapa is the only option that offers a combination of the said two ingredients.

 

According to the amendment made to the reimbursement of antidiabetic combination therapies that are applied from this month, Zemiglo will be allowed to be additionally prescribed to patients taking metformin and SGLT-2 inhibitors whose glucose level is not properly controlled.

 

Zemidapa will be allowed to be prescribed with reimbursement starting on the 1st of next month.

 

LG Chem conducted a Phase III trial on 748 patients whose blood sugar is not adequately controlled with existing two-drug combination therapy.

 

The company had invested over KRW 20 billion in the clinical trial.

 

Results showed that the three-drug Zemiglo+metformin+dapagliflozin combination has a greater blood glucose level improvement effect than the two-drug combination (metformin+dapagliflozin or Zemiglo+metformin).

 

In-Cheol Hwang, Head of LG Chem’s Chronic Disease Business Unit, said, "The combination of the DPP-4 inhibitor that stimulates insulin production and the SGLT-2 inhibitor that excretes glucose from the body, have a complementary therapeutic effect.

 

By securing large-scale clinical evidence in domestic patients, and building on the unique competitiveness of Zemidapa of being the only combination of the two ingredients, we plan to continue to lead the KRW 1 trillion domestic diabetes market.” In line with the release of Zemidapa, LG Chem plans to hold symposiums to inform about the clinical efficacy of Zemidapa for healthcare professionals in the nation.

 

After launching Zemiglo, a new diabetes drug developed by LG Chem in 2012, the company has additionally launched the combinations Zemimet and Zemiro based on Zemiglo.

 

According to UBIST, a market research institute, prescriptions for the Zemiglo product line last year recorded KRW 133 billion.